Cholesterol management guidance just underwent its most significant revision in nearly a decade. And for the first time, the update carries a new name to match a broader scope. What was previously issued as cholesterol management guidelines has been renamed the 2026 Dyslipidemia Guidelines, reflecting a shift from a narrow focus on LDL-lowering toward a more comprehensive model of atherogenic lipoprotein risk.
For those of us treating women through perimenopause, menopause, and beyond, this is exciting and important news. It formalizes several things many of us have been doing in practice for years, like testing ApoB and Lp(a), thinking in decades rather than a single risk score, and taking reproductive history seriously as cardiovascular data.
Below is my breakdown of some of the most important changes, what you can implement in your practice this week, and where the guidelines still have room for improvement and growth!
1. Lifetime Risk Replaces the 10-Year Lens
The most conceptually important shift in this update is the move away from the pooled cohort equations that have anchored cardiovascular risk assessment for nearly two decades. The new standard is the PREVENT calculator, which incorporates additional variables and critically estimates both 10-year and 30-year risk.
This is especially important for women, whose cardiovascular risk is shaped by variables that shift across the lifespan. Because of the cardioprotective effect of endogenous estrogen, women routinely present with reassuring 10-year risk scores well into their 40s, even with mildly elevated LDL or early metabolic dysfunction. Now, for the first time, there’s a recommended tool that accounts for a longer time horizon that can actually incorporate these hormonal variables.
Clinical action: If you’re not already using the PREVENT calculator in your intake or annual risk review, this is the moment to switch. Run both the 10-year and 30-year outputs for every female patient over 30, and use the 30-year number as your primary conversation-starter for early intervention.
2. ApoB and Lp(a) Are Now Formally Included — But the Targets Haven’t Caught Up
This is the change I’m most enthusiastic about clinically, and the one with the most immediate, actionable impact on how you order labs starting today.
Why ApoB matters: LDL-C measures the volume of cholesterol carried by LDL particles. ApoB counts the actual number of atherogenic particles circulating in the blood. These two values are discordant in up to 25% of patients (most often in patients with metabolic syndrome, elevated triglycerides, or insulin resistance, all of which increase in prevalence through the menopause transition). ApoB has consistently outperformed LDL-C as a predictor of future cardiac events, and its formal inclusion in these guidelines is a meaningful validation of what functional and integrative practitioners have understood for some time.
Why Lp(a) matters: Lipoprotein(a) is a largely genetically determined, independent risk factor. Think of it as a “sticky” particle that increases the likelihood cholesterol infiltrates the coronary arteries, this on top of whatever LDL or ApoB burden is already present. The guidelines now recommend Lp(a) be measured at least once in every adult’s lifetime, formally establishing it as standard of care rather than a specialty or “if indicated” test. For every 50 mg/dL increase, lifetime cardiac risk rises roughly 11%. Patients above 90 mg/dL (190 nmol/L) carry a nearly 2-3x higher lifetime risk of coronary heart disease.
Where I’d push further: While I’m genuinely glad both markers made it into the guidelines, the specific numeric treatment thresholds are still anchored to LDL-C, not to ApoB or Lp(a). We have both markers now being considered and being recommended but no guideline or target values. In Functional Medicine, we have our own targets we have adopted but would be nice to have this worked into these guidelines.
A note on retesting Lp(a): Because it’s largely genetically determined, a single lifetime measurement is technically considered sufficient by the guidelines. In practice, I recommend checking it more than once across a woman’s reproductive lifespan, specifically before, during, and after the menopause transition, and again if hormone therapy is initiated. Lp(a) levels are known to rise with menopause and can shift 5-15% on estrogen therapy, so intermittent monitoring around these transitions gives you more clinically actionable information than a single early-life data point.
Clinical action, starting this week: Add ApoB and Lp(a) to your standard lipid panel for every new female patient over 35, and for existing patients at their next visit. If your current lab requisition doesn’t default to including these, update your standing orders now. We teach and talk through goals for these values in your Adapt Practitioner Certification and Fellowship Program.
3. Reproductive History Is Now a Formal Risk Modifier
This is, in my view, long overdue and one of the most clinically significant additions for anyone working with women’s health across the lifespan. For the first time, the guidelines explicitly incorporate reproductive risk factors (factors that affect only female patients) as formal modifiers of future cardiovascular risk:
- Hypertensive disorders of pregnancy (preeclampsia, gestational hypertension)
- Gestational diabetes
- Preterm delivery (before 37 weeks gestation)
- Small-for-gestational-age birth (birthweight below the 10th percentile)
- Recurrent spontaneous pregnancy loss
- Early menarche
- Polycystic ovarian syndrome (PCOS)
- Early menopause (40-45 years old)
- Premature menopause (before 40 years old)
The clinical stakes for these women are substantial. Preeclampsia doubles lifetime risk of stroke and heart disease, and women with a preeclampsia history who go on to have a cardiac event are three times more likely to die from it. Gestational diabetes raises lifetime type 2 diabetes risk 7-10 fold and doubles cardiovascular disease risk. And premature menopause increases cardiovascular disease risk by roughly 40%, with Black women three times more likely to experience premature menopause than white women, compounding an already elevated baseline risk and underscoring a real health equity dimension to this guidance.
Clinical action — build this into your intake: Most standard intake forms don’t capture this history:
- “Were you ever diagnosed with preeclampsia, gestational hypertension, or gestational diabetes during any pregnancy?”
- “Did you experience a preterm delivery, or were you told a baby was small for gestational age?”
- “Have you had two or more pregnancy losses?”
- “At what age did you get your first period?”
- “Have you been diagnosed with PCOS?”
- “At what age did your periods stop, or, if you’re still cycling, is there a family history of early menopause?”
Nothing fancy here, just a few additional screening questions. If a patient answers yes to any of the above, treat it as you would a first-degree family history of premature CVD: a reason to lower your threshold for lipid testing, risk calculation, and earlier intervention, regardless of what a 10-year or 30-year risk score suggests.
Honorable Mentions
Expanded Pharmacologic Options
The guidelines formally incorporate newer non-statin therapies into treatment algorithms: bempedoic acid (Nexletol), an oral non-statin shown to reduce cardiovascular events in the CLEAR OUTCOMES trial, and the PCSK9 inhibitors evolocumab and alirocumab, whose role was further clarified by the VESALIUS-CV trial showing reduced cardiovascular events in high-risk primary-prevention patients (those without a prior heart attack or stroke). Inclisiran (Leqvio), a twice-yearly injectable, also now has a formally defined place in the algorithm, though its cardiovascular event data is still maturing.
This matters clinically because it broadens options for patients who decline statins, cannot tolerate them, or need more aggressive intervention than statin monotherapy provides. Statin intolerance, while less common than perceived, does trend higher in women. so having validated, guideline-endorsed alternatives is a meaningful addition to shared decision-making conversations, particularly for patients who’ve previously been told statins were their only option.
CAC Scoring Gets a Bigger Role — With Some Limitations
Coronary artery calcium (CAC) scoring — an imaging study that quantifies calcified plaque in the coronary arteries — now carries a Class 1 recommendation as a decision tool for patients where the choice to initiate treatment is genuinely uncertain. I’m glad to see it formalized: it’s inexpensive, widely accessible, and gives us objective data to resolve ambiguity in intermediate-risk patients. A score above zero, particularly above 100, generally supports initiating treatment; a score of zero can reasonably support a trial of lifestyle-focused management for the right patient.
But CAC has a real and clinically important limitation that’s worth reviewing with your patients: it only detects calcified plaque, which takes years to develop. In younger women in particular — the guidelines only recommend CAC starting at age 45 for women, versus 40 for men — a score of zero is common even when soft, non-calcified plaque is already present and simply invisible to this modality. A zero CAC in a 42-year-old with an elevated Lp(a) and a preeclampsia history should not be read the same way as a zero CAC in a 60-year-old with no other risk factors.
This is part of why, for select patients (particularly younger women with elevated Lp(a), strong family history, or other reproductive risk modifiers where a negative CAC doesn’t fully reassure), I favor coronary CT angiography (CTA) over CAC alone. CTA visualizes the artery wall directly and can detect soft, non-calcified plaque that CAC scoring will miss entirely. It’s a more resource-intensive test and not appropriate as a universal screening tool, but understanding when CAC’s ceiling has been reached and, when CTA is the more informative next step, is a worth building into your clinical decision-making, and into how you counsel patients about what a “clean” calcium score does and doesn’t tell them.
Bringing This Into Practice This Week
None of the changes above require new infrastructure or a long runway. Three things you can implement immediately:
- Update your lab orders. Add ApoB and Lp(a) to your standard panel for female patients over 35.
- Switch your risk calculator. Use PREVENT instead of the pooled cohort equations, and document both the 10-year and 30-year outputs.
- Update your intake form. Add the reproductive history screening questions above if they aren’t already part of your standard workup.
Where We Still Need Movement
These guidelines are genuine progress with decades of women’s cardiovascular data finally showing up in formal clinical guidance, and markers many of us have already been using clinically now carry official standing. But there’s more work ahead. We still need ApoB- and Lp(a)-anchored treatment thresholds rather than LDL-C serving as the default number. And the guidelines remain notably silent on the cardioprotective role of hormone therapy for women close in age to menopause.
Not everything here is perfect. But it’s exciting to see substantive progress toward a cardiovascular risk framework that actually reflects female physiology!
